Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

2021171 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet Infectious Diseases

Volume 22, Issue 3, pp. 329-340

Field-Weighted Citation Impact: 9.24